Benefits of SGLT2 inhibitors combining with renin-angiotensin-system blockers on cardiovascular outcomes in chronic kidney disease patients: A systemic review and meta-analysis.
Med Clin (Barc)
; 159(2): 65-72, 2022 07 22.
Article
in En, Es
| MEDLINE
| ID: mdl-34872768
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Renal Insufficiency, Chronic
/
Sodium-Glucose Transporter 2 Inhibitors
Type of study:
Clinical_trials
/
Systematic_reviews
Limits:
Humans
Language:
En
/
Es
Journal:
Med Clin (Barc)
Year:
2022
Type:
Article
Affiliation country:
China